Generic drug options did not reduce prices paid for the cancer therapy imatinib (Gleevec), according to a Health Affairs study released this week.
After nearly two years of generic competition the price for a month of treatment dropped by only 10 percent, according to authors from Vanderbilt University School of Medicine and University of North Carolina at Chapel Hill.